Vincera Pharma, Inc. (VINC)
|Net Income (ttm)||n/a|
|Trading Day||January 26|
|Day's Range||19.83 - 21.17|
|52-Week Range||9.35 - 21.67|
PALO ALTO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer throug...
Business combination transaction with LifeSci Acquisition Corp. was completed on December 23, 2020
Vincera Pharma, a clinical-stage biopharmaceutical company, researches and develops new therapies to address unmet medical needs for the treatment of cancer. The company's product pipeline includes VIP152 that is in Phase 1 clinical trials for the treatment of solid tumors/nonHodgkin lymphoma and acute myeloid leukemia; VIP236, a small molecule drug conjugate for solid tumors; VIP943 for the treatment of leukemias and myelodysplastic syndromes; and VIP924 for B-cell malignancies. It also develops VIP217, an oral PTEFb/CDK9 inhibitor. The compan... [Read more...]
Dr. Ahmed M. Hamdy
|Stock Exchange |
|Ticker Symbol |
According to one analyst, the rating for Vincera Pharma stock is "Strong Buy" and the 12-month stock price forecast is 33.00.